• Skip to main content
  • Skip to primary navigation
  • Home
  • Community Schedule
  • Hospital Medicines (HML)
  • Application Tracker

Pharmac - Te Pātaka Whaioranga. Pharmac - Te Pātaka Whaioranga. Pharmac - Te Pātaka Whaioranga.

  • Te Rārangi Rongoā Pharmaceutical Schedule

    Pharmaceutical Schedule

    The Pharmaceutical Schedule lists all the medicines funded for New Zealanders.

    • Community Schedule

      Search for funded medicines

    • Hospital Medicines (HML)

      Search for funded medicines for hospitals

    • Schedule Updates

      The monthly update to the Schedule

    • Schedule resources

      Additional resources for community and hospital Schedules

    • About the Schedule

      An introduction to the Schedule

    • Rules of the Schedule

      For pharmacists and prescribers using the Schedule

    • Hospital Medical Devices

      Read about our work with contracting medical devices for hospitals

  • Te pūtea me ngā umanga rongoā Medicine funding and supply

    Medicine funding and supply

    Find out how PHARMAC decides what medicines to fund, how to apply for a medicine to be funded and other questions about medicines you might have.

    • Make an application

      Apply to have a medicine funded for everyone or an individual

    • Medicine notices (includes supply issues)

      Brand changes, supply issues and discontinuations

    • The funding process

      How funding applications are assessed

    • What you need to know about medicines

      Learn about generic medicines, biosimilars, vaccines and getting your prescription

    • Medicine supply management

      Order condoms and smoking cessation products. Learn about PHARMAC's role in medicine supply

  • Ngā pūrere hauora a te hōhipere Hospital medical devices

    Hospital medical devices

    PHARMAC contracts with device suppliers to ensure our hospitals can buy medical devices at fairer prices.

    • Category Information

      Find out which types of medical device we have contracted and the ones we're working on

    • Growing our role in medical devices

      The goal for our work in medical devices

    • Device Advice

      Read and subscribe to our devices newsletter

  • Treaty of Waitangi Te Tiriti o Waitangi

    Te Tiriti o Waitangi

    • Te Whaioranga

      PHARMAC's Māori Responsiveness Strategy

    • Hauora Arotahi

      The Māori health areas of focus

    • Programmes to support Māori health

      Scholarships, awards and programmes

    • How we work with Whānau Ora

      Working with communities and Māori health providers

  • Ngā karere me ngā rauemi News and resources

    News and resources

    Check the current consultations, RFPs and tenders. Find our key resources for prescribers, pharmacists, researchers and the public.

    • Consultations and decisions

      Consultations, RFPs, tenders and our decisions

    • News and updates

      Latest news from PHARMAC

    • Order publications

      How to order a printed publication

    • Seminars

      Watch previous seminars

    • COVID-19

      Our response to COVID-19

    • PHARMAC's research

      Articles and reports produced by PHARMAC

  • Mō About

    About

    Learn more about who PHARMAC is and our goals. There are details about our Board and our expert advisors.

    • Strategic Direction

      Our plan to deliver the best health outcomes for New Zealanders

    • Pacific Responsiveness Strategy

      Our strategy to support Pacific people to live healthy lives

    • Te Tiriti o Waitangi

      Our commitment to being Tiriti partners

    • What we do

      Learn more about PHARMAC's role and how we support the health system

    • Who we are

      Our Board, our senior leaders, and experts

    • How we get expert advice

      Advice we seek to make decisions

    • Working at PHARMAC

      Explore current vacancies

    • Contact us

      How to get in touch

Search

Search PHARMAC's corporate website

Search for funded medicines and Special Authority forms

Search for medicines funded in hospitals.

Check the progress of a medicine funding application

  1. Home
  2. About
  3. What we do
  4. Accountability information
  5. Official Information Act
  6. 2020 OIA Responses

2020 OIA Responses

Index of OIA responses sent in 2020

  • 22 December 2020: OIA response: funding for blood glucose monitors via Named Patient Pharmaceutical Assessment

  • 21 December 2020: OIA response: average age of initiation of statin therapy in New Zealand

  • 21 December 2020: OIA response: cannabidiol with tetrahydrocannabinol (Sativex) clinical advice paper for PTAC

  • 11 December 2020: OIA response: Special authority data for temozolomide for the treatment of neuroendocrine tumours

  • 4 December 2020: OIA response: organisations who responded to proposal to fund two new medicines for type 2 diabetes

  • 3 December 2020: OIA response: funding data for rare disorders medicines

  • 3 December 2020: OIA response: FreeStyle Libre flash glucose monitor and Dexcom continuous glucose monitor, Tandem insulin pump

  • 2 December 2020: OIA response: anti-vascular endothelial growth factor (“anti-VEGF”) agents

  • 27 November 2020: OIA response: special authority approvals for adalimumab, etanercept, secukinumab,

  • 25 November 2020: OIA response: Special authority funding data for insulin pump consumables

  • 24 November 2020: OIA response: funding for blood glucose monitors and test strips

  • 19 November 2020: OIA response: decision to change the tetanus vaccine and immunisation schedule

  • 18 November 2020: OIA response: cost of funding oral vinorelbine

  • 18 November 2020: OIA response: information relating to funding continuous glucose monitors (CGMs)

  • 16 November 2020: OIA response: public funding of Trikafta

  • 16 November 2020: OIA response: consultation submissions for proposal to modify PHARMAC’s approach t

  • 16 November 2020: OIA response: fingolimod use and annual expenditure (2017-2020)

  • 05 November 2020: OIA response: ustekinumab NPPA applications for Crohn’s disease and/or ulcerative

  • 2 November 2020: OIA response: Hydroxychloroquine in the treatment of COVID-19

  • 28 October 2020: OIA response: Special Authority approval data for olaparib, rituximab

  • 20 October 2020: OIA response: Special Authority data for somatropin and pegylated interferon alfa-2

  • 16 October 2020: OIA response: Canterbury DHB distribution/dispensing data for influenza vaccine, an

  • 15 October 2020: OIA response: Information related to PHARMAC employee remuneration/salary bands

  • 14 October 2020: OIA response: Dispensing data for siltuximab, tocilizumab and bedaquiline

  • 12 October 2020: OIA response: Decision process for funding criteria for teriparatide (Forteo)

  • 11 October 2019: OIA response: Cancer drugs data

  • 2 October 2020: OIA response: Multiple scerosis (MS) patient numbers

  • 1 October 2020: OIA response: Funding data for ustekinumab via the Exceptional Circumstances Framewo

  • 1 October 2020: OIA response: Special Authority funding data for lenalidomide (Revlimid)

  • 20 November 2020: OIA response: implications of switching from pharmaceuticals to medicinal cannabis

  • 30 September 2020: OIA response: Funding data for Hylo-Fresh eye drops

  • 29 September 2020: OIA response: Information regarding Named Patient Pharmaceutical Assessment (NPPA

  • 28 September 2020: OIA response: Application data for multiple sclerosis treatments

  • 24 September 2020: OIA response: Cost-benefit analysis for ustekinumab

  • 24 September 2020: OIA response: Patient numbers and cost utility analysis for ivacaftor (Kalydeco)

  • 18 September 2020: OIA response: Funding plans for progesterone only oral contraceptive pill (POP) d

  • 3 September 2020: OIA response: Erectile dysfunction medications available and funded in New Zealand

  • 3 September 2020: OIA response: Cost of funding tramadol in 2019

  • 28 August 2020: OIA response: Droperidol supply data

  • 28 August 2020: OIA response: Data for funded intravenous iron usage

  • 28 August 2020: OIA response: Data for HIV antiretroviral usage

  • 17 August 2020: OIA response: Information regarding subsidised prescriptions for goserelin and leupr

  • 13 August 2020: OIA response: Special Authority data for pembrolizumab and nivolumab for June 2020

  • 10 August 2020: OIA response: Information regarding PTAC subcommittee minutes

  • 5 August 2020: OIA Response: Information regarding Spinraza funding

  • 30 July 2020: OIA response: Dispensing NPPA B medicines

  • 29 July 2020: OIA response: Information related to the prescription and/or use of generic medicines

  • 28 July 2020: OIA response: annual funding volumes of trastuzumab

  • 28 July 2020: OIA response: indemnities sought from pharmaceutical companies for out-of-stock/supply issues

  • 27 July 2020: OIA response: funding and purchase data for lenalidomide and bortezomib 

  • 20 July 2020: OIA response: medicines funded for the treatment of multiple sclerosis

  • 20 July 2020: OIA response: annual funding of food thickeners Aptamil and Nutilis

  • 20 July 2020: OIA response: hospital purchasing data and Special Authority approvals for azacitidine

  • 16 July 2020: OIA response: Special Authority approvals for methylphenidate for treatment of ADHD vs narcolepsy

  • 16 July 2020: OIA response: Hydroxychloroquine for the treatment or prevention of COVID-19

  • 16 July 2020: OIA response: Anaesthetic gases

  • 16 July 2020: OIA response: Special Authority data for Risperdal Consta, Zyprexa Relprevv, Invega Sustenna

  • 15 July 2020: OIA response: payments to the New Zealand Drug Foundation

  • 13 July 2020: OIA response: Special Authority and funding data for anti-epileptic medicines

  • 9 July 2020: OIA response: Special Authority approval data for enoxaparin sodium

  • 3 July 2020: OIA response: Special Authority data for ADHD medicines

  • 3 July 2020: OIA response: Ministerial briefings – medicines supply and funding decisions

  • 3 July 2020: OIA response: ministerial briefings

  • 25 June 2020: OIA response: NPPA applications and exceptional circumstances applications for lamotri

  • 19 June 2020: OIA response: Discontinuation of phenelzine sulphate

  • 19 June 2020: OIA response: Pembrolizumab and nivolumab

  • 19 June 2020: OIA response: Ritalin

  • 18 June 2020: OIA response: Nationwide Special Authority data by immunology indication

  • 11 June 2020: OIA response: Official complaints

  • 25 May 2020: OIA response: Cost increases caused by COVID-19

  • 18 May 2020: OIA response: Funding applications declined

  • 23 April 2020: OIA response - Consumer Advisory Committee (CAC)

  • 20 April 2020: OIA response: Widely dispensed medicines

  • 16 April 2020: OIA response - Fentanyl

  • 7 April 2020: OIA response - PTAC’s record of consideration for hypothyroidism Nov 2018

  • 3 April 2020: OIA response - Levothyroxine supply

  • 31 March 2020: OIA response: Vinorelbine

  • 31 March 2020: OIA response: Effect of COVID-19 on medicine supply

  • 18 March 2020: OIA response - Supply of funded medicine

  • 17 March 2020: OIA Response: Medicines from China

  • 17 March 2020: OIA response: Anti-epileptic medicines

  • 17 March 2020: OIA response: PrEP Data

  • 16 March 2020: OIA response: Preparations for COVID-19

  • 13 March 2020: OIA response: Security of supply of medicines

  • 12 March 2020: OIA response: Supply of cladribine and dacarbazine

  • 9 March 2020: OIA response: New Zealand Pharmaceutical Market

  • 28 February 2020: OIA response: Utrogestan SA

  • 27 February 2020: OIA response: Anti-rejection medications for transplant patients

  • 24 February 2020: OIA response: Lamotrigine brand change

  • 24 February 2020: OIA response: Cilazapril with hydrochlorothiazide

  • 24 February 2020: OIA response - Ibrutinib

  • 20 February 2020: OIA response - PHARMAC's budget

  • 11 February 2020: OIA response: Lamotrigine exceptional circumstances applications

  • 4 February 2020: OIA response: Hospital purchases of special foods

  • 3 February 2020: OIA response: Tafamidis and amyloidosis

  • 31 January 2020: OIA response: Mirena statistical information

  • 30 January 2020: OIA response: Zapril

  • 14 January 2020: OIA response: Asthma inhaler devices dispensed

Back to top

Pharmac - Te Pātaka Whaioranga.

  • Community Schedule
  • Hospital Medicines (HML)
  • Application Tracker
  • Contact us
  • Follow us
  • Facebook
  • LinkedIn
  • Twitter

Shielded site.

  • Copyright
  • Disclaimer
  • Privacy statement
  • Subscribe

New Zealand Government.